Secondary endpoints can be validly analysed, even if the primary endpoint does not provide clear statistical significance
Secondary outcomes are extremely important in early phase trials when the full benefits are still being discovered.
https://pubmed.ncbi.nlm.nih.gov/9408718/
Secondary endpoints can be validly analysed, even if the primary...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 701 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 751 | 1 |
View Market Depth
| Last trade - 09.57am 04/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable